Celcuity Inc. (CELC)

Celcuity is a cancer diagnostics and precision medicine company that develops and markets proprietary cell-based testing platforms designed to guide treatment selection for patients with cancer. The company operates in the oncology and precision medicine sector, using patient-derived cell cultures to assess how individual tumours respond to different drugs, helping physicians choose targeted therapies most likely to work for each patient’s specific disease.

The insight: tumours behave differently in every patient

Celcuity’s bet is that the most accurate way to predict whether a drug will work against a patient’s cancer is to test it directly in that patient’s tumour cells.

The insight driving Celcuity is deceptively simple: cancer is not one disease but thousands of individual variations, and even two patients with the same cancer type may respond entirely differently to the same drug. Traditional oncology treatment relied on broad categories — lung cancer, breast cancer — and standard protocols. Precision medicine flips the question: instead of asking “what is the standard treatment for this type of cancer?”, the practitioner asks “what drug will work best for this patient’s unique tumour?”

Celcuity’s platform uses living cells derived directly from a patient’s tumour. The company grows those cells in culture and tests them against a panel of drugs, measuring which ones cause the tumour cells to die or stop growing. The results are sent back to the oncologist, who can then select therapy based not on population averages but on what actually worked against that individual’s cancer in the laboratory.

How the test is performed and what it costs

Celcuity’s primary offering is a test marketed as CELsigna. A sample — typically a biopsy or fluid aspirate — is collected from the patient and sent to Celcuity’s laboratory. Technicians isolate the living cancer cells, grow them, and then expose them to a standardised panel of anticancer drugs. The assay measures which drugs most strongly suppress tumour growth. Results are returned to the treating physician as a ranked report, usually within one to two weeks.

The test is sold primarily to hospital systems, cancer centres, and occasionally directly to insurers who may recommend it for specific patient cohorts. Coverage from major insurers varies by region and changes periodically, making insurance reimbursement a moving target. Patients may encounter the test through their oncologist’s recommendation, though uptake is limited by the need for the physician to know about it, perceive value in it, and have insurance coverage in place.

The revenue model is transactional: Celcuity earns money each time a test is performed. The amount varies depending on the payer — some insurers reimburse more than others — but the company has worked to establish laboratory-developed test billing codes and insurance contracts. Volume growth and successful payor negotiations are thus central to the business.

Technology, validation, and the evidence question

Celcuity’s technology is built on the assumption that ex-vivo tumour cell response predicts in-vivo clinical benefit — that is, if the test shows a drug works in the patient’s own cells in a dish, that patient is more likely to respond clinically when given that drug. The company has invested heavily in validating this premise through clinical studies and retrospective analyses.

The challenge is that cell-based assays are imperfect representations of what happens in a living organism. A tumour is not just cancer cells but an ecosystem including immune cells, blood vessels, and supporting tissue — all of which influence drug response. Growing cells in culture removes most of that complexity. Over time, cell lines may also drift from the original tumour characteristics. Competing diagnostic approaches — particularly genomic profiling, which sequences the DNA mutations in the tumour — also claim to predict drug response, albeit through a different mechanism.

Celcuity’s differentiation is the claim that a functional cell-based test captures more of the real-world complexity than genetic mutation analysis alone. Whether that translates to consistently better clinical outcomes, better survival, or better quality of life remains an area of ongoing study. The company publishes research and works with academic partners to build that evidence base, but the field of precision oncology testing is still maturing, and no single approach is yet definitive across all cancer types.

Market pressures and the path to scale

Celcuity faces several headwinds. First, awareness is limited. Many oncologists are not yet familiar with cell-based assays, and without physician push, the test will not be ordered. This means the company must invest in clinical education and marketing to drive adoption — a slow, capital-intensive process in healthcare.

Second, insurance coverage is uneven. Major insurers have gradually expanded coverage for certain precision oncology tests, but reimbursement rates and coverage policies vary. A test that is covered in one state may not be in another, and coverage can change. This creates unpredictable revenue and requires sustained payor relations work.

Third, competition is real. Large diagnostic companies including Quest Diagnostics and LabCorp have entered the precision oncology space, as have genomics-focused firms. Government and academic laboratories also offer similar testing. Celcuity must establish that its cell-based approach offers clear enough advantages to justify adoption over cheaper or simpler alternatives.

Fourth, clinical validation is ongoing. While the company has generated supportive data, broader, randomised trials showing that patients whose treatment is guided by the CELsigna test have materially better outcomes than those treated without it would accelerate adoption. Such trials are expensive and take years to complete.

Reading the business and watching forward

Celcuity’s operating model is that of a specialised laboratory service. Revenue depends on test volume, average reimbursement, and the cost per test. Margins can be strong once volume is sufficient to absorb fixed laboratory costs, but the company has historically operated at a loss whilst building scale and pursuing clinical evidence.

Investors should monitor quarterly test volume, the trajectory of revenue per test, the breadth of payor coverage, and progress on clinical studies. Any major insurer signing a coverage agreement, or announcement of a randomised controlled trial validating the platform, moves the needle. Conversely, competitive losses, coverage denials from large payors, or clinical data showing no benefit to cell-based selection over simpler approaches would be material headwinds.

The company’s path to profitability depends on reaching sufficient volume that per-test margins support overhead, and on securing durable insurance reimbursement. It is a high-stakes bet on the idea that precision oncology based on functional testing is not just scientifically sound but sufficiently superior to guide clinical practice — and that Celcuity’s particular technology is the best way to realise that benefit.